Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 19 Carcinoma, Renal Cell 13 Parkinson Disease 4, Autosomal Dominant Lewy Body 10 Endometrial Neoplasms 6 Neoplasms 4 Biliary Tract Neoplasms 4 Neuroendocrine Tumors 3 Melanoma 3 Liver Neoplasms 3 Vulvar Neoplasms 2 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 von Hippel-Lindau Disease 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Penile Neoplasms 1 Multiple Endocrine Neoplasia Type 1 1 Lung Neoplasms 1 Kidney Neoplasms 1 Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer 1

Interventions

Specimen Handling 51 Carboplatin 49 pembrolizumab 45 Magnetic Resonance Spectroscopy 43 Pemetrexed 39 Cisplatin 34 Paclitaxel 24 durvalumab 23 osimertinib 20 Nivolumab 19 Gemcitabine 19 Radiosurgery 17 Docetaxel 17 atezolizumab 14 Taxes 12 Radiotherapy 12 Immunoglobulin G 12 Disulfides 12 130-nm albumin-bound paclitaxel 12 Etoposide 11 Educational Status 11 Biopsy 11 Radiation 10 Drug Therapy 10 Blood Specimen Collection 10 Platinum 9 Early Intervention, Educational 9 Cetuximab 9 Methods 8 Bevacizumab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × lenvatinib × 90 days × Clear all

NCT05384015 2026-04-30

PEERS

Fundación GECP

Phase 2 Active not recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡